Phase 3 data of mdc-IRM first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia
15 November 2021
Phase 3 data of mdc-IRM, first product based on MedinCell’s […]
FOR ANY FURTHER INFORMATION,
PLEASE CONTACT:
communication@medincell.com
Our news
Bringing you the latest!
All news
MedinCell: mdc-IRM’s Phase 3 data to be presented for the first time by Teva at Psych Congress 2021
21 October 2021
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia
31 August 2021
Participation terms in the MedinCell Combined General Meeting
4 August 2021
MedinCell announces the availability of its 2020/2021 Universal Registration Document including the Annual Financial Report
28 July 2021
MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development
14 June 2021
Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin
19 April 2021
Press
Communication leader
MedinCell
David Heuzé
david.heuze@medincell.com
+33 (0)6 83 25 21 86
Media
NewCap
Nicolas Merigeau
medincell@newcap.eu
+33 (0)1 44 71 94 94
Investors
Investor Relations
NewCap
Louis-Victor Delouvrier /
Alexia Faure
medincell@newcap.eu
+33 (0)1 44 71 94 94